Association between metformin use and progression of monoclonal gammopathy of undetermined signifi cance to multiple myeloma in US veterans with diabetes mellitus: A population-based retrospective cohort study

The Lancet Haematology

Volumn 2, Issue 1, 2015, Pages e30-e36

  Chang, Su Hsin ^a,b   Luo, Suhong ^a,b   O'Brian, Katiuscia K ^a,b   Thomas, Theodore S ^a,b   Colditz, Graham A ^b   Carlsson, Nils P ^b   Carson, Kenneth R ^a,b  

^a Veterans Affairs Saint Louis Health Care System   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; M PROTEIN; METFORMIN;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY ANALYSIS; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; VETERAN;

AGED; DIABETES MELLITUS; FEMALE; HUMANS; MALE; METFORMIN; MIDDLE AGED; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; RISK FACTORS; VETERANS;

EID: 84923068525     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(14)00037-4     Document Type: Article

References (36)

1. National Cancer Institute. SEER Cancer Statistics Review, 1975-2010. June 14, 2013. http://seer.cancer.gov/csr/1975_2010 (accessed April 14, 2014).
2. Landgren O. Monoclonal gammopathy of undetermined signifi cance and smoldering multiple myeloma: biological insights and early treatment strategies. Hematology Am Soc Hematol Educ Program. 2013; 2013: 478-87.
3. Rajkumar SV, Kyle RA, Therneau TM, et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined signifi cance. Blood 2005; 106: 812-17.
4. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined signifi cance. N Engl J Med 2002; 346: 564-69.
5. Merlini G. Determining the signifi cance of MGUS. Blood 2014; 123: 305-07.
6. Alexander DD, Mink PJ, Adami HO, et al. Multiple myeloma: a review of the epidemiologic literature. International journal of cancer. Int J Cancer 2007; 120 (suppl 12): 40-61.
7. Birmann BM, Giovannucci EL, Rosner BA, Colditz GA. Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study. Cancer Prev Res 2014; 7: 33-41.
8. Perez-Persona E, Vidriales MB, et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain signifi cance and smoldering multiple myeloma based on multiparameter fl ow cytometry analysis of bone marrow plasma cells. Blood 2007; 110: 2586-92.
9. Turesson I, Kovalchik SA, Pfeiff er RM, et al. Monoclonal gammopathy of undetermined signifi cance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden. Blood 2014; 123: 338-45.
10. Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined signifi cance. Blood 2003; 102: 3759-64.
11. Birmann BM, Neuhouser ML, Rosner B, et al. Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium. Blood 2012; 120: 4929-37.
12. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-79.
13. Medina EA, Oberheu K, Polusani SR, Ortega V, Velagaleti GV, Oyajobi BO. PKA/AMPK signaling in relation to adiponectin's antiproliferative eff ect on multiple myeloma cells. Leukemia 2014; 28: 2080-89.
14. Ben Sahra I, Le Marchand-Brustel Y, Tanti JF, Bost F. Metformin in cancer therapy: a new perspective for an old antidiabetic drug? Mol Cancer Ther 2010; 9: 1092-99.
15. Wu W, Merriman K, Nabaah A, et al. The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 2014; 111: 628-36.
16. Currie CJ, Poole CD, Gale EA. The infl uence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766-77.
17. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ 2005; 330: 1304-05.
18. Lai SW, Liao KF, Chen PC, Tsai PY, Hsieh DP, Chen CC. Antidiabetes drugs correlate with decreased risk of lung cancer: a population-based observation in Taiwan. Clin Lung Cancer 2012; 13: 143-48.
19. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009; 32: 1620-25.
20. Yang X, So WY, Ma RC, et al. Low HDL cholesterol, metformin use, and cancer risk in type 2 diabetes: the Hong Kong Diabetes Registry. Diabetes Care 2011; 34: 375-80.
21. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use with ICD-9-CM administrative data: diff ering perspectives. J Clin Epidemiol 1993; 46: 1075-79.
22. International Myeloma Working Group. Criteria for the classifi cation of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-57.
23. Savas LS, del Junco DJ, Bastian LA, Vernon SW. Mortality ascertainment of women veterans: a comparison of sources of vital status information, 1979-2002. Med Care 2009; 47: 125-28.
24. Sohn MW, Arnold N, Maynard C, Hynes DM. Accuracy and completeness of mortality data in the Department of Veterans Aff airs. Popul Health Metr 2006; 4: 2.
25. Carson KR, Bates ML, Tomasson MH. The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplant 2014; 49: 1009-15.
26. Beason TS, Chang SH, Sanfilippo KM, et al. Infl uence of body mass index on survival in veterans with multiple myeloma. Oncologist 2013; 18: 1074-79.
27. Suissa S, Azoulay L. Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care 2012; 35: 2665-73.
28. Klein JP, Moeschberger ML. Survival analysis: techniques for censored and truncated data, 2nd edn. New York: Springer, 2003.
29. Burn J, Gerdes AM, Macrae F, et al. Long-term eff ect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-87.
30. Hill PG, Forsyth JM, Rai B, Mayne S. Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies. Clin Chem 2006; 52: 1743-48.
31. Baumann P, Mandl-Weber S, Emmerich B, Straka C, Schmidmaier R. Inhibition of adenosine monophosphate-activated protein kinase induces apoptosis in multiple myeloma cells. Anticancer Drugs 2007; 18: 405-10.
32. Vu K, Busaidy N, Cabanillas ME, et al. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 2012; 12: 355-62.
33. Castillo JJ, Mull N, Reagan JL, Nemr S, Mitri J. Increased incidence of non-Hodgkin lymphoma, leukemia, and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies. Blood 2012; 119: 4845-50.
34. Agha Z, Lofgren RP, VanRuiswyk JV, Layde PM. Are patients at Veterans Aff airs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med 2000; 160: 3252-57.
35. Kazis LE, Miller DR, Clark J, et al. Health-related quality of life in patients served by the Department of Veterans Aff airs: results from the Veterans Health Study. Arch Intern Med 1998; 158: 626-32.
36. Morgan RO, Teal CR, Reddy SG, Ford ME, Ashton CM. Measurement in Veterans Aff airs Health Services Research: veterans as a special population. Health Serv Res 2005; 40: 1573-83.